Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
about
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cellsNew molecular targets in mantle cell lymphomaNatural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesPhase 2 study of weekly bortezomib in mantle cell and follicular lymphomaOxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivoMantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraMolecular targeted approaches in mantle cell lymphoma.Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideProteasome inhibitors in mantle cell lymphomaProteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewA phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasInduction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomibBortezomib for the treatment of non-Hodgkin's lymphomaTreatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccinationHistone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.Will new drugs change the standard of care for patients with mantle cell lymphoma?The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
P2860
Q24654958-EB97BF69-5CA5-4DFF-B2F3-D44D65149E8BQ26821766-5AB2B293-AFCB-464A-978F-3508443C6B52Q28073020-B8A2DBF0-1133-4348-BB4C-1AC3C13931A1Q30570945-6FE5534E-DD9E-44CB-9381-0C4D22772DC0Q33669018-B7FDB435-09DD-44FC-90FF-339A7B459006Q33741142-9E68712C-6786-4283-9307-89151E6B1137Q33798624-66764F5C-9DB7-462D-A8EE-F912B7866241Q33894754-9CE4F623-A8AD-414B-BD6F-CC6D5A33CA92Q34414452-31AFD8A9-ECA1-4817-87C6-9AE2959BA13EQ34534191-4133F0AE-9F20-4080-A36B-FEB1C92CAB94Q34568868-100B7319-511E-474E-80C4-BD8C57277F2CQ35127368-D2A610C6-B890-42E5-B479-B272E068CF06Q35183027-89C6064B-61EE-4D94-82AD-60D6FA53356AQ35939690-B3650D0C-64D0-4619-A14A-234F0372060BQ35989980-177CCA06-A76B-42CD-B252-45BE99C0E5D8Q36028745-D2E649FA-452A-42B2-956A-C89105A0EBB6Q36408216-BC050E43-2628-4D3D-8266-8F20D6C57423Q36438027-B2FF1000-1B39-4407-9773-3302C340738CQ36703448-063CE59E-1D25-46CF-AE5A-9510460C73AFQ36782473-6FF29E9F-259B-4798-B414-8A1800D2D471Q36868056-C11CBE41-1C67-4D00-89CE-4A7D91D340EFQ36874310-F34A26EB-12AF-4AA5-B891-0136C45E1968Q37277238-C357DF2C-A0A2-46D7-8B55-6E60686D7E06Q37301751-EB63775F-7721-4770-86F2-35927DE8AE67Q37400663-48A72425-97D6-4F0B-AAB0-83B76FD17067Q37774667-195020C5-792E-4261-911B-55962B1FED03Q38088360-C42E2136-3558-4222-997D-678542FC5DB0Q38658549-CB4E7931-F386-48A9-9EEF-A73A391B7777Q38891634-7CBBEF01-56D8-4604-A696-F6BC75C28F3BQ38962956-9F5DCE65-4108-4269-B7B5-2314F933D5D9Q39029195-DFE47CB2-B92C-4D95-95EA-2F5CBF8AE4C5Q39414811-EF3EB8F0-D424-4D02-9CC3-AFAC9F9D5ACDQ39527860-7D33B252-3B9A-47B4-A381-43BADE077742Q39588189-F845F99B-7CF9-4295-AE9B-5955003DDBE1Q39620587-F3162A61-23B5-4858-98B6-C4F23CA2DED2Q39717620-5AE7554C-84C6-4E70-A442-C5B30B509F70Q39914674-89B8AD48-1EFD-4AB6-A1A3-2B180857FA04Q44795969-87289ACB-2142-4213-83F0-C6F15C90506DQ45324502-053E0FC5-00D0-4284-9FE7-3A7EEADA02C3Q46697939-7ED1B5CB-CF31-4AB8-9737-3B4C823A75D2
P2860
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Synergistic interaction of the ...... zomib in mantle cell lymphoma.
@en
type
label
Synergistic interaction of the ...... zomib in mantle cell lymphoma.
@en
prefLabel
Synergistic interaction of the ...... zomib in mantle cell lymphoma.
@en
P2093
P1476
Synergistic interaction of the ...... zomib in mantle cell lymphoma.
@en
P2093
Christian Jakob
Claudia Fleissner
Ivana von Metzler
Jessica Rademacher
Marleen Rosche
Martin Kaiser
Orhan Sezer
Susanne Rötzer
Ulrike Heider
P304
P356
10.1111/J.1600-0609.2007.00995.X
P577
2007-12-20T00:00:00Z